Familial lecithin:cholesterol acyltransferase (LCAT) deficiency is a well-defined inborn error of metabolism, where the enzymatic deficiency (LCAT) has been clarified and also the chromosomal defect (chromosome 16q22) is localized. The disease is to-day known all around the world and 50 patients from 26 families are known to-day. Corneal opacities have been found in all patients and appear early in life. The opacities have a characteristic appearance which makes it rather easy to get the correct diagnosis of this disease. Near the limbus, a pronounced opacity of annular shape resembling a marked arcus lipoides senilis occurs. The opacities are composed of numerous minute grayish dots and are localized to the parenchyma and evenly distributed in all layers of the stroma. In polarized light, crystals that may be cholesterol have been seen in both cornea and the fundus. Excess unesterified cholesterol and phospholipid has been found in cornea. The disease is also characterized by slight anemia and proteinuria and sometimes lipemic plasma, but patients without anemia and proteinuria have also been described. All lipoproteins are abnormal in familial LCAT deficiency. The individual lipoprotein fractions are all heterogeneous and characterized by a higher amount of free cholesterol than normal. Rapidly developing renal insufficiency in adult age often appears in this type of familial renal disease. Kidney transplantation may be necessary. LCAT has now been characterized as a glycoprotein with 416 aminoacids + hydrophobic leader sequence of 24 aminoacids and an apparent Mr of 63 kD. Plans exist to proceed with genomic cloning of the LCAT gene from normal DNA and from various patients.

Download full-text PDF

Source
http://dx.doi.org/10.3109/13816818809031494DOI Listing

Publication Analysis

Top Keywords

lcat deficiency
12
acyltransferase lcat
8
anemia proteinuria
8
lcat
6
familial
4
familial lecithin
4
cholesterol
4
lecithin cholesterol
4
cholesterol acyltransferase
4
deficiency
4

Similar Publications

LCAT deficiency promotes hepatocellular carcinoma progression and lenvatinib resistance by promoting triglyceride catabolism and fatty acid oxidation.

Cancer Lett

January 2025

Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, 200032, PR China. Electronic address:

Lecithin cholesterol acyltransferase (LCAT), a crucial enzyme in lipid metabolism, plays important yet poorly understood roles in tumours, especially in hepatocellular carcinoma (HCC). In this study, our investigation revealed that LCAT is a key downregulated metabolic gene and an independent risk factor for poor prognosis in patients with HCC. Functional experiments showed that LCAT inhibited HCC cell proliferation, migration and invasion.

View Article and Find Full Text PDF

A 59-year-old Japanese woman was referred for an extremely low level of circulating high-density lipoprotein cholesterol (HDL-C). The serum HDL-C level had long been within the normal range but suddenly decreased asymptomatically to 7 mg/dL. She had no typical symptoms associated with familial lecithin, cholesterol acyltransferase deficiency (FLD), including proteinuria, anemia, and corneal opacity.

View Article and Find Full Text PDF

Novel pathogenic variant in the LCAT gene in a compound heterozygous patient with fish-eye disease and a mild phenotype.

J Clin Lipidol

October 2024

Department of Cardiovascular Medicine and Hypertension, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.

Article Synopsis
  • Low HDL-cholesterol and corneal opacity are linked to diseases like fish-eye disease and familial LCAT deficiency, with diagnosis typically requiring both clinical and biochemical tests, particularly LCAT activity, which isn't accessible in all clinics.
  • A case study revealed a patient with compound heterozygous FED whose CE/TC ratio was normal, contrasting with the expectation of low levels due to LCAT gene variants.
  • The patient showed 20% LCAT α-activity, which is enough to normalize their CE/TC ratio but insufficient to prevent corneal opacity, highlighting a distinction in LCAT activity's effects on disease symptoms.
View Article and Find Full Text PDF
Article Synopsis
  • LCAT is an essential enzyme for maintaining cholesterol balance and plays a role in preventing atherosclerosis; dysfunction can lead to severe disorders without current treatments.
  • Research explores using small molecule positive allosteric modulators (PAMs) to improve LCAT function, although proving their effectiveness against atherosclerosis is complex.
  • The study found that certain compounds, like SGLT2 inhibitors, activate LCAT, suggesting new insights into diabetes medications and highlighting the usefulness of molecular simulations in drug development.
View Article and Find Full Text PDF

Purpose: To present ocular clinical, histological, systemic, and genetic findings of a patient with familial lecithin-cholesterol acyltransferase (LCAT) deficiency caused by a novel genetic variant of the LCAT gene associated with secondary corneal amyloidosis.

Methods: Case report.

Results: A 74-year-old woman presented with decreased visual acuity (VA), sensitivity to light, and progressive whitening of both corneas for approximately 20 years.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!